Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Digistain
AddedMar 20, 2024
UpdatedJun 18, 2026
Digistain

Digistain

Revolutionizing breast cancer care with swift, affordable diagnostics.

HQ
Newport Pagnell, Buckinghamshire, GB
Founded
2019
Accelerator
Y Combinator logoY CombinatorS21
Overview
Compare
Fundraising
Employees
Website

Digistain, founded at Imperial College London, is dedicated to revolutionizing breast cancer diagnostics. The company aims to provide swift, affordable, and accurate diagnostic solutions to improve patient outcomes. Digistain offers an MHRA-cleared technology that leverages AI to analyze key biomarkers, significantly reducing the time and cost associated with traditional genomic testing. Their primary focus is on breast cancer recurrence risk profiling, providing a faster and more accessible alternative to existing methods.

Notable figures affiliated with Digistain include leading researchers from Imperial College London. The company has garnered attention and support from key investors in the healthcare sector. Among its achievements, Digistain's technology has been recognized for its predictive equivalence to traditional genomic tests, marking a significant advancement in breast cancer care. The impact of Digistain's innovation is profound, offering hope and improved diagnostic options to millions of breast cancer patients worldwide.

Digistain - Similar Companies

Signatur Biosciences logo

Signatur Biosciences

signatur.bio

Isabl logo

Isabl

isabl.io

Clear Gene logo

Clear Gene

cleargene.com

Epinoma logo

Epinoma

epinoma.com

Precipio logo

Precipio

precipiodx.com

Histofi logo

Histofi

histofi.com

Breath Diagnostics logo

Breath Diagnostics

HistoWiz logo

HistoWiz

histowiz.com

Pictor Labs logo

Pictor Labs

Epi One logo

Epi One

epi-one.com

Instapath Inc. logo

Instapath Inc.

instapathbio.com

AOA Dx logo

AOA Dx

aoadx.com

Droplet Biosciences logo

Droplet Biosciences

dropletbiosci.com

Data Driven Bioscience logo

Data Driven Bioscience

BloodQ logo

BloodQ

bloodq.com

Digistain - Quick Facts

Who are Digistain's competitors?

Companies similar to Digistain include Signatur Biosciences, Isabl, Clear Gene and Epinoma.

When was Digistain founded?

Digistain was founded in 2019.

Where is Digistain's headquarters located?

Digistain's headquarters is located in Newport Pagnell, Buckinghamshire, GB.

How much has Digistain raised to-date?

As of Sep 9, 2021, Digistain has raised a total of $125k (USD).

How many employees does Digistain have?

Digistain has 8 employees as of Feb 24, 2024.

Digistain - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Diagnostics
Tags
  • Biotech
  • Data Information
  • Healthcare
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified